Segmentation by types of therapy further refines the market taxonomy into four sub‑categories: synthetic hormones, bioidentical hormones, stem‑cell‑based interventions, and ovarian tissue transplantation. Synthetic hormones, the most mature class, dominate with an estimated 45 % share, reflecting their lower cost and extensive safety data. Bioidentical hormones, chemically identical to endogenous steroids, capture approximately 25 % of the market, propelled by patient preference for “natural” options despite comparable efficacy. Emerging stem‑cell therapies, still largely investigational, hold a 20 % share, driven by early‑phase trial outcomes suggesting ovarian function regeneration. Ovarian tissue transplantation, a niche surgical approach, contributes the remaining 10 % and is limited by donor availability and procedural complexity. Each type’s proportion mirrors its clinical maturity, reimbursement landscape, and adoption rate, collectively informing the total market valuation.